Article in Journal of neurovirology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Jacqueline Renee KulbeUniversity of California, San Diego Department of Psychiatry, San Diego, CA, USA.
Alexandra Anh LeUniversity of California, San Diego Department of Psychiatry, San Diego, CA, USA.
Michael ManteUniversity of California, San Diego Department of Neurosciences, San Diego, CA, USA.
Jazmin FlorioUniversity of California, San Diego Department of Neurosciences, San Diego, CA, USA.
Anna Elizabeth LairdUniversity of California, San Diego Department of Psychiatry, San Diego, CA, USA.
Mary K SwintonUniversity of California, San Diego Department of Psychiatry, San Diego, CA, USA.
Robert A RissmanUniversity of California, San Diego Department of Neurosciences, San Diego, CA, USA.
Jerel Adam FieldsUniversity of California, San Diego Department of Psychiatry, San Diego, CA, USA. Jafields@health.ucsd.edu.ORCID 0000-0002-8168-1412
University of California San Diego · USAutism Research Institute · USUC San Diego Health System · US
Funding
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jessica Lynette Montoya · 2001 to 2026
$50.4M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI · 2020 to 2026
$27.8M
Cannabis and Pathogenic Mechanisms influencing Blood Brain Barrier Function in HIVR01DA058405 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jerel Adam Fields, Jennifer E Iudicello · 2023 to 2026
$5.0M
Psychiatry Research Residency Training TrackR25MH101072 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NEAL R SWERDLOW · 2013 to 2026
$2.8M
The role of TFAM alterations in HIV- and ART-induced mitochondrial dysfunction in the brainR01MH128108 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jerel Adam Fields · 2022 to 2026
$2.3M
The role of TREM2 in Alzheimer's disease neuropathogenesis in HIV+ individualsR56AG066215 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIELDS, JEREL ADAM · 2020 to 2020
Central nervous system (CNS) dysfunction remains prevalent in people with HIV (PWH) despite effective antiretroviral therapy (ART). There is evidence that low-level HIV infection and ART drugs may contribute to CNS damage in the brain of PWH with suppressed viral loads. As cannabis is used at a higher rate in PWH compared to the general population, there is interest in understanding how HIV proteins and ART drugs interact with the endocannabinoid system (ECS) and inflammation in the CNS. Therefore, we investigated the effects of the HIV envelope protein gp120 and tenofovir alafenamide (TAF) on cannabinoid receptor 1 (CB
Indexed as
Anti-HIV AgentsHIV InfectionsAdenineAnimalsHippocampusHIV Envelope Protein gp120HumansMiceMice, TransgenicReceptors, CannabinoidAdenineAnti-HIV AgentsHIV Envelope Protein gp120Receptors, CannabinoidAstrogliosisEndocannabinoidgp120HIVTAF
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
GP120 and tenofovir alafenamide alter cannabinoid receptor 1 expression in hippocampus of mice. · full record | OpenQuestion